Edaravone mimics sphingosine-1-phosphate-induced endothelial barrier enhancement in human microvascular endothelial cells

Kazuyoshi Omori, Yasushi Shikata, Kei Sarai, Naomi Watanabe, Jun Wada, Noriko Goda, Noriyuki Kataoka, Kenichi Shikata, Hirofumi Makino

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Edaravone is a potent scavenger of hydroxyl radicals and is quite successful in patients with acute cerebral ischemia, and several organ-protective effects have been reported. Treatment of human microvascular endothelial cells with edaravone (1.5 μM) resulted in the enhancement of transmonolayer electrical resistance coincident with cortical actin enhancement and redistribution of focal adhesion proteins and adherens junction proteins to the cell periphery. Edaravone also induced small GTPase Rac activation and focal adhesion kinase (FAK; Tyr576) phosphorylation associated with sphingosine-1-phosphate receptor type 1 (S1P1) transactivation. S1P1 protein depletion by the short interfering RNA technique completely abolished edaravone-induced FAK (Tyr576) phosphorylation and Rac activation. This is the first report of edaravone-induced endothelial barrier enhancement coincident with focal adhesion remodeling and cytoskeletal rearrangement associated with Rac activation via S1P1 transactivation. Considering the well-established endothelial barrier-protective effect of S1P, endothelial barrier enhancement as a consequence of S1P1 transactivation may at least partly be the potent mechanisms for the organ-protective effect of edaravone and is suggestive of edaravone as a therapeutic agent against systemic vascular barrier disorder.

Original languageEnglish
JournalAmerican Journal of Physiology - Cell Physiology
Volume293
Issue number5
DOIs
Publication statusPublished - Nov 2007

Fingerprint

Endothelial cells
Lysosphingolipid Receptors
Endothelial Cells
Transcriptional Activation
Phosphorylation
Focal Adhesions
Chemical activation
Adhesion
Adherens Junctions
Focal Adhesion Protein-Tyrosine Kinases
Proteins
Acoustic impedance
Monomeric GTP-Binding Proteins
neurotensin mimic 1
sphingosine 1-phosphate
phenylmethylpyrazolone
Brain Ischemia
Electric Impedance
Hydroxyl Radical
Small Interfering RNA

Keywords

  • Focal adhesion
  • Rac
  • Sphingosine-1-phosphate receptor type 1
  • Transmonolayer electrical resistance

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cell Biology
  • Physiology

Cite this

Edaravone mimics sphingosine-1-phosphate-induced endothelial barrier enhancement in human microvascular endothelial cells. / Omori, Kazuyoshi; Shikata, Yasushi; Sarai, Kei; Watanabe, Naomi; Wada, Jun; Goda, Noriko; Kataoka, Noriyuki; Shikata, Kenichi; Makino, Hirofumi.

In: American Journal of Physiology - Cell Physiology, Vol. 293, No. 5, 11.2007.

Research output: Contribution to journalArticle

@article{f50ad07d30094714b80fe6ca377174d4,
title = "Edaravone mimics sphingosine-1-phosphate-induced endothelial barrier enhancement in human microvascular endothelial cells",
abstract = "Edaravone is a potent scavenger of hydroxyl radicals and is quite successful in patients with acute cerebral ischemia, and several organ-protective effects have been reported. Treatment of human microvascular endothelial cells with edaravone (1.5 μM) resulted in the enhancement of transmonolayer electrical resistance coincident with cortical actin enhancement and redistribution of focal adhesion proteins and adherens junction proteins to the cell periphery. Edaravone also induced small GTPase Rac activation and focal adhesion kinase (FAK; Tyr576) phosphorylation associated with sphingosine-1-phosphate receptor type 1 (S1P1) transactivation. S1P1 protein depletion by the short interfering RNA technique completely abolished edaravone-induced FAK (Tyr576) phosphorylation and Rac activation. This is the first report of edaravone-induced endothelial barrier enhancement coincident with focal adhesion remodeling and cytoskeletal rearrangement associated with Rac activation via S1P1 transactivation. Considering the well-established endothelial barrier-protective effect of S1P, endothelial barrier enhancement as a consequence of S1P1 transactivation may at least partly be the potent mechanisms for the organ-protective effect of edaravone and is suggestive of edaravone as a therapeutic agent against systemic vascular barrier disorder.",
keywords = "Focal adhesion, Rac, Sphingosine-1-phosphate receptor type 1, Transmonolayer electrical resistance",
author = "Kazuyoshi Omori and Yasushi Shikata and Kei Sarai and Naomi Watanabe and Jun Wada and Noriko Goda and Noriyuki Kataoka and Kenichi Shikata and Hirofumi Makino",
year = "2007",
month = "11",
doi = "10.1152/ajpcell.00524.2006",
language = "English",
volume = "293",
journal = "American Journal of Physiology",
issn = "0002-9513",
publisher = "American Physiological Society",
number = "5",

}

TY - JOUR

T1 - Edaravone mimics sphingosine-1-phosphate-induced endothelial barrier enhancement in human microvascular endothelial cells

AU - Omori, Kazuyoshi

AU - Shikata, Yasushi

AU - Sarai, Kei

AU - Watanabe, Naomi

AU - Wada, Jun

AU - Goda, Noriko

AU - Kataoka, Noriyuki

AU - Shikata, Kenichi

AU - Makino, Hirofumi

PY - 2007/11

Y1 - 2007/11

N2 - Edaravone is a potent scavenger of hydroxyl radicals and is quite successful in patients with acute cerebral ischemia, and several organ-protective effects have been reported. Treatment of human microvascular endothelial cells with edaravone (1.5 μM) resulted in the enhancement of transmonolayer electrical resistance coincident with cortical actin enhancement and redistribution of focal adhesion proteins and adherens junction proteins to the cell periphery. Edaravone also induced small GTPase Rac activation and focal adhesion kinase (FAK; Tyr576) phosphorylation associated with sphingosine-1-phosphate receptor type 1 (S1P1) transactivation. S1P1 protein depletion by the short interfering RNA technique completely abolished edaravone-induced FAK (Tyr576) phosphorylation and Rac activation. This is the first report of edaravone-induced endothelial barrier enhancement coincident with focal adhesion remodeling and cytoskeletal rearrangement associated with Rac activation via S1P1 transactivation. Considering the well-established endothelial barrier-protective effect of S1P, endothelial barrier enhancement as a consequence of S1P1 transactivation may at least partly be the potent mechanisms for the organ-protective effect of edaravone and is suggestive of edaravone as a therapeutic agent against systemic vascular barrier disorder.

AB - Edaravone is a potent scavenger of hydroxyl radicals and is quite successful in patients with acute cerebral ischemia, and several organ-protective effects have been reported. Treatment of human microvascular endothelial cells with edaravone (1.5 μM) resulted in the enhancement of transmonolayer electrical resistance coincident with cortical actin enhancement and redistribution of focal adhesion proteins and adherens junction proteins to the cell periphery. Edaravone also induced small GTPase Rac activation and focal adhesion kinase (FAK; Tyr576) phosphorylation associated with sphingosine-1-phosphate receptor type 1 (S1P1) transactivation. S1P1 protein depletion by the short interfering RNA technique completely abolished edaravone-induced FAK (Tyr576) phosphorylation and Rac activation. This is the first report of edaravone-induced endothelial barrier enhancement coincident with focal adhesion remodeling and cytoskeletal rearrangement associated with Rac activation via S1P1 transactivation. Considering the well-established endothelial barrier-protective effect of S1P, endothelial barrier enhancement as a consequence of S1P1 transactivation may at least partly be the potent mechanisms for the organ-protective effect of edaravone and is suggestive of edaravone as a therapeutic agent against systemic vascular barrier disorder.

KW - Focal adhesion

KW - Rac

KW - Sphingosine-1-phosphate receptor type 1

KW - Transmonolayer electrical resistance

UR - http://www.scopus.com/inward/record.url?scp=36048961354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36048961354&partnerID=8YFLogxK

U2 - 10.1152/ajpcell.00524.2006

DO - 10.1152/ajpcell.00524.2006

M3 - Article

C2 - 17686998

AN - SCOPUS:36048961354

VL - 293

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0002-9513

IS - 5

ER -